Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
pdmFlu vaccine · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| pdmFlu vaccine 1 | EXPERIMENTAL | - |
| pdmFlu vaccine 2 | EXPERIMENTAL | - |
| pdmFlu vaccine 3 | EXPERIMENTAL | - |
| pdmFlu vaccine 4 | EXPERIMENTAL | - |
| pdmFlu vaccine 5 | EXPERIMENTAL | - |
| pdmFlu vaccine 6 | EXPERIMENTAL | - |
| pdmFlu vaccine 7 | EXPERIMENTAL | - |
| pdmFlu vaccine 8 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Licensed influenza vaccine | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| pdmFlu vaccine | BIOLOGICAL | Intramuscular injection |
| Placebo | BIOLOGICAL | Intramuscular injection |
| Licensed influenza vaccine | BIOLOGICAL | Intramuscular injection |
Key Inclusion Criteria: \- Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study. Key Exclusion Criteria: \- Does not meet seasonal influenza vaccine requirements per coho...
The pdmFlu vaccine is an investigational modified RNA vaccine being studied for the prevention of pandemic influenza, referred to in the trial as Grippe. It is designed to produce an immune response against pandemic flu strains. The vaccine is currently in Phase 1 clinical development and is not yet approved.
The pdmFlu vaccine is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer is conducting clinical research on this modified RNA vaccine candidate for pandemic influenza prevention.
The pdmFlu vaccine is in Phase 1 clinical development. It is an investigational vaccine, meaning it has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the vaccine remains under study for safety and immune response.
The pdmFlu vaccine was studied in a Phase 1 clinical trial registered as NCT06179446, titled 'A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza.' The trial enrolled 157 participants in the United States and has been completed.
No, the pdmFlu vaccine is not a monoclonal antibody. Although the modality is listed as monoclonal antibody in some records, the clinical trial describes it as a modified RNA vaccine. The vaccine is designed to elicit an immune response against pandemic influenza.
Yes, the Phase 1 clinical trial for the pdmFlu vaccine was randomized, double-blind, and placebo-controlled. The study enrolled healthy volunteers aged 18 years and older in the United States, with a total of 157 participants.